Clinical trial
SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION [EGP]: Can the Glucagon-like Peptide-1 [GLP-1] Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
NCT03331289 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION [EGP]: Can the Glucagon-like Peptide-1 [GLP-1] Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 28, 2018
- Completion date
- November 4, 2022
- Enrollment
- 107 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.